In 2008, another phase I study was carried by Dai et al., based on the use of EEVs vaccination, in which ascites-derived EEVs (Aex) combined with granulocyte-macrophage colony stimulating factor (GM-CSF) were used in the immunotherapy of colorectal cancer (CRC) [255]. Here, CSF2 is linked to colorectal cancer.